Stocks · News reference
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dyne Therapeutics shares are trading lower. The company announced it will present additional one-year Phase 1/2 ACHIEVE trial data for zeleciment basivarsen in DM1 at the 31st WMS Congress and the 2026 AANEM Annual Meeting.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons
Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.